Key Takeaways
- Turnaround driven by governance, not markets: Gross margin hit a historic 50.5% and opex fell ~INR40 crores sequentially, but management attributes the reset to internal discipline and a deliberate shift toward profitable products, not to an industry recovery.
- Vizag is the FY26 growth bet: The mothballed ibuprofen plant is being converted into a multipurpose HPAPI and polymers facility, with a Q1 FY26 restart and zero under-recoveries promised for the full year.
- Ibuprofen dependency unwound: The company has dramatically reduced its reliance on plain-vanilla ibuprofen, pivoting into derivatives, analogs, and direct-compressible forms, while dismissing the SI Group plant closure as immaterial to global supply.
- Balance sheet repair on track: Debt-to-EBITDA is already under 2x and management expects it below 1.5x if guidance is met, with a path to near net-cash by FY27.
- What to watch next quarter: Whether the Q4 exit run rate of INR400 crores materializes, the pace of Vizag’s operational restart, and any sign that CRAMS is scaling toward its 10%-of-sales FY26 target.
The Turnaround: Governance Over Market Tailwinds
- Gross margin at a record: Margins jumped from 44.5% to 50.5% sequentially, driven by a mix shift toward niche, small-volume, higher-margin products launched from older development work, plus a higher CRAMS contribution in the quarter.
- Opex slashed without compliance risk: Like-to-like opex fell from ~INR130 crores in Q4 FY24 to ~INR113 crores in Q2, achieved through capacity utilization planning and cycle time management, with management insisting quality and compliance were not compromised.
- The reset is deliberate, not cyclical: Management framed the improvement as a "course correction" away from chasing unprofitable revenue, with heightened governance now the primary operating principle.
- Base opex can inch lower still: The base has come down from ~INR135 crores to ~INR115 crores and can be reduced a little more, though next year Vizag will run at peak operations for at least three quarters, which will add costs back.
Arun Kumar: "I just think that we have reset our business from being all over the place to be very focused on what we want to achieve. And the numbers that you're seeing is a reflection of a course correction and not necessarily the market dynamics."
Vizag Facility: The FY26 Growth Engine
- From single-product plant to multipurpose asset: The Vizag facility, previously a dedicated ibuprofen plant that was mothballed, is being converted into a multipurpose site that will include high-potency API (HPAPI) capabilities and expanded polymers capacity.
- Polymers business is sold out: The polymers line, which involves complex chemistry with few players outside India, is fully booked, and Vizag has been retrofitted to add more capacity for that portfolio. Solara supplies nearly all ANDA players in the US for this product.
- Restart timeline and contribution: The facility is guided to start by Q1 FY26, with three full quarters of contribution that year and zero under-recoveries promised for the full fiscal year.
- Ibuprofen will remain, but as a second source: Vizag will continue to make ibuprofen and its derivatives, but in much smaller quantities, serving as a backup rather than the primary revenue driver.
- Capex commitment: The company has an internal capex plan of approximately INR100 crores for the Vizag conversion.
- Long asset-turn timeline: Management cautioned that Vizag will probably take at least two years before it reaches a 1x to 1.2x asset turn.
Arun Kumar: "We have fully sold for capacity and Vizag in fact has been retrofitted to add more capacities around that line of items. It's a very complex chemistry, not many players out of India."
Ibuprofen & API Pricing: Hitting the Floor
- Dependency dramatically reduced: Over the last six months, Solara has shifted tactics away from plain ibuprofen into derivatives, analogs, and direct-compressible forms, materially derisking its historical concentration.
- Pricing has likely bottomed: Management believes API pricing has "more or less stabilized" and "probably we have hit the bottom," though it called any six-month pricing forecast "an impossible question."
- SI Group closure is a non-event: The closed US ibuprofen plant is a tiny facility at 5,000 MTA, dwarfed by over 20,000 tons of new global capacity added in the last two years, and all current players are already FDA-approved, so no supply gap or opportunity emerges.
- Industry margin dynamics: When price pressures ease, there is a lag before margins expand as companies work through cost-reduction programs, manufacturing improvements, and newer technologies like enzymatic routes.
Arun Kumar: "We work in an industry where we can't predict what happens next week. So, you're asking me to answer an impossible question."
CRAMS & New Bets: Early Days
- CRAMS is sub-scale but growing: The business is currently below INR100 crores annualized and described as "suboptimal," but management is on track to hit its target of 10% of sales by FY26. No quarterly CRAMS number was disclosed.
- Peptides entry is cautious: Solara has entered the peptide value chain, manufacturing for some larger players, but management was dismissive of the hype, calling peptides "more fashionable than anything else" and noting "everybody is in it." The company does no peptide work for group companies or big pharma, and it is early days with no revenue potential quantified.
- DMF strategy is consolidation, not expansion: The company plans only four to five DMF filings over the next two years, prioritizing cost improvement and customer onboarding on the existing book before filing new products.
- Biosecurity Act tailwind is real but slow: Companies are reviewing sourcing strategies and supply chain security, and Solara is seeing benefits, but "not a flood."
Arun Kumar: "Well, I think so it's -- see, everybody talks about peptides. It's more fashionable than anything else. Everybody is in it."
Balance Sheet & Tax: Repair Underway
- Leverage improving fast: Debt-to-EBITDA is already under 2x and is expected to drop below 1.5x if the company hits its guidance.
- Path to net cash by FY27: Management does not expect to be net cash positive next year, estimating roughly 1.5 years, putting the target around FY27 when the company should be "in a very strong position or very close to being net cash."
- Zero tax through FY26: The company is at a 0% tax rate due to carry-forward losses, a position that will hold through FY25 and FY26 before changing in FY27.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q4 FY25 exit run rate | INR400 crores revenue | Q4 FY25 |
| Vizag plant restart | Back on stream, zero under-recoveries for the full year | Q1 FY26 |
| Debt-to-EBITDA | Below 1.5x | If guidance is met (implied FY25) |
| Net cash position | Very strong position or very close to net cash | FY27 |
| CRAMS revenue share | 10% of sales | FY26 |
| DMF filings | Four to five new filings | Over the next two years |
| Tax rate | 0% | FY25 and FY26; changes from FY27 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹347-odd cr, Q4 exit run rate guided to ₹400 cr |
| Gross margin | 50.5%, historical high, up 620 bps YoY and approximately flat QoQ |
| Gross margin (Q1 FY25) | 44.5%, sequential jump to 50.5% driven by cost containment and product mix |
| Operating expenditure | ₹113 cr, down from ₹130 cr in Q4 FY24 and a base of approx ₹135 cr |
| Net debt | Below ₹500 cr, adjusted for uncalled rights issue money of ₹222 cr |
| Debt-to-EBITDA | Under 2x, expected to improve to less than 1.5x if guidance is hit |
| Regulated market share | 76% of revenue, stable sequentially |
| Ibuprofen group revenue share | ~25% of global revenues, the largest product group |
| CRAMS annualized revenue | Less than ₹100 cr, on track for ~7-8% of guided ₹1,500 cr revenue |
| CRAMS revenue target (FY26) | 10% of sales |
| Vizag capacity mothballed | 33-35% of total capacities, plant being retrofitted to multipurpose including HPAPI |
| Vizag gross block | ~₹500 cr, net block ~₹250 cr, with additional capex plan of ~₹100 cr |
| Vizag asset turn target | 1x to 1.2x, expected to take at least two years from restart |
| Vizag restart timeline | Q1 FY26, with zero under-recoveries expected in FY26 |
| New DMF filings planned | 4 to 5 over the next two years, focus on commercializing existing portfolio |